Icecure Medical is trading 5.03% up at $1.67 before the September 30, 2026 session, with no fresh company-specific announcement identified to explain the move. - The latest identified major catalyst was China’s regulatory approval for ProSense on September 10; it is not a new overnight development. - The broader pre-market backdrop is modestly positive, but the provided major index moves are below 0.5% and do not clearly explain the gain.